NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
Vad Lazari Ph.D., appointed to newly created position of…
19 April 2023/by WebadmNRG Therapeutics Announces International Scientific Advisory Board
Stevenage, UK, 30 March 2023 - NRG Therapeutics, Ltd., an innovative…
30 March 2023/by WebadmNRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
Stevenage, UK, 22 February 2023 - NRG Therapeutics, Ltd., an…
22 February 2023/by WebadmNRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
Gilles Ouvry Ph.D, appointed to newly created position of…
9 February 2023/by WebadmNRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS
£16 million Series A led by Omega Funds, to advance disease-modifying…
9 November 2022/by WebadmNRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project
NRG Therapeutics Ltd., an innovative neuroscience company targeting…
30 June 2022/by WebadmNRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neurone Disease
£2.68 million Biomedical Catalyst (BMC) early-stage award…
30 May 2022/by WebadmNRG Therapeutics Completes MND Therapeutic Analysis Project with Medicines Discovery Catapult Supported by an Innovate UK EDGE Grant
NRG’s second therapeutic programme to explore brain penetrant…
1 March 2022/by WebadmNRG Therapeutics Launches MND Drug Discovery Programme and Announces new Collaboration in Australia
NRG’s second therapeutic programme to explore brain penetrant…
16 December 2021/by Webadm
